病毒诱导的肝细胞癌风险：最新进展与未来挑战
Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges.
作者信息
Lupberger Joachim, Baumert Thomas F
机构信息
Institut National de la Santé et de la Recherche Médicale, U1110, 67000 Strasbourg, France.
Institut de Recherche sur les Maladies Virales et Hépatiques, Université de Strasbourg, 67000 Strasbourg, France.
出版信息
J Clin Med. 2021 Dec 31;11(1):208. doi: 10.3390/jcm11010208.
Abstract
Chronic viral hepatitis is a key risk factor for liver fibrosis and hepatocellular carcinoma (HCC) [...].
摘要
慢性病毒性肝炎是肝纤维化和肝细胞癌（HCC）的关键危险因素[...]。
相似文献
1
Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges.病毒诱导的肝细胞癌风险：最新进展与未来挑战
J Clin Med. 2021 Dec 31;11(1):208. doi: 10.3390/jcm11010208.
2
Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.Smad3的接头磷酸化促进肝细胞癌慢性病毒性肝炎中的纤维致癌作用。
World J Gastroenterol. 2014 Nov 7;20(41):15018-27. doi: 10.3748/wjg.v20.i41.15018.
3
Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.STAT3 和 HK-II 在乙型肝炎病毒和丙型肝炎病毒相关性肝细胞癌中的表达差异。
J Med Virol. 2016 Sep;88(9):1552-9. doi: 10.1002/jmv.24498. Epub 2016 Mar 8.
4
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.接受 DAA 治疗的晚期丙型肝炎患者新诊断的肝细胞癌：一项前瞻性人群研究。
J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16.
5
Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.慢性乙型肝炎患者肝细胞癌发生的预测模型
World J Gastroenterol. 2016 Oct 7;22(37):8314-8321. doi: 10.3748/wjg.v22.i37.8314.
6
Hepatitis B: liver fibrosis and hepatocellular carcinoma.乙型肝炎：肝纤维化与肝细胞癌。
Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):911-5. doi: 10.1016/j.gcb.2009.06.001. Epub 2009 Jul 4.
7
Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma.家族肝癌史和乙型肝炎病毒感染对肝癌发病风险的协同作用。
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1636-45.e1-3. doi: 10.1016/j.cgh.2013.04.043. Epub 2013 May 10.
8
Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?丙型肝炎病毒纤维化进展后病毒应答后肝细胞癌风险：谁需要筛查，需要筛查多久？
World J Gastroenterol. 2021 Oct 28;27(40):6737-6749. doi: 10.3748/wjg.v27.i40.6737.
9
Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?慢性病毒性肝炎肝细胞癌的监测：是否到了个体化的时代？
World J Gastroenterol. 2021 Sep 7;27(33):5536-5554. doi: 10.3748/wjg.v27.i33.5536.
10
Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi.新型乙型肝炎和肝细胞癌生物标志物：HBcrAg 和 M2BPGi 的临床意义。
Int J Mol Sci. 2020 Jan 31;21(3):949. doi: 10.3390/ijms21030949.
本文引用的文献
1
Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma.宿主表观遗传改变与乙型肝炎病毒相关肝细胞癌
J Clin Med. 2021 Apr 16;10(8):1715. doi: 10.3390/jcm10081715.
2
Genomics of Viral Hepatitis-Associated Liver Tumors.病毒性肝炎相关肝肿瘤的基因组学
J Clin Med. 2021 Apr 22;10(9):1827. doi: 10.3390/jcm10091827.
3
CD8 T Cell Responses during HCV Infection and HCC.丙型肝炎病毒感染和肝癌过程中的CD8 T细胞反应
J Clin Med. 2021 Mar 2;10(5):991. doi: 10.3390/jcm10050991.
4
Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development.慢性病毒性肝炎期间的促纤维化信号与肝癌风险：生物标志物的开发
J Clin Med. 2021 Mar 2;10(5):977. doi: 10.3390/jcm10050977.
5
Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis.探寻丙型肝炎病毒诱导肝癌发生的表观遗传印记
J Clin Med. 2021 Feb 2;10(3):551. doi: 10.3390/jcm10030551.
6
Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B.肝损伤有利于慢性乙型肝炎中 HBV 整合和克隆性肝细胞的清除。
Hepatol Int. 2021 Feb;15(1):60-70. doi: 10.1007/s12072-020-10125-y. Epub 2021 Feb 3.
7
Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control.丙型肝炎病毒根除或乙型肝炎病毒控制后肝细胞癌风险的分层
J Clin Med. 2021 Jan 19;10(2):353. doi: 10.3390/jcm10020353.
8
Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection.丙型肝炎病毒感染直接抗病毒治疗后肝细胞癌风险的免疫机制
J Clin Med. 2021 Jan 10;10(2):221. doi: 10.3390/jcm10020221.
9
Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk.肝细胞癌风险的临床与分子预测
J Clin Med. 2020 Nov 26;9(12):3843. doi: 10.3390/jcm9123843.
10
Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.肝细胞癌预防的风险因素、发病机制及策略：重点关注二级预防及其转化挑战
J Clin Med. 2020 Nov 25;9(12):3817. doi: 10.3390/jcm9123817.
Zotero 插件